Business Wire

NY-MOODY'S-ANALYTICS

10.6.2019 08:32:06 CEST | Business Wire | Press release

Share
Moody’s Analytics to Provide Certification for Hungarian Mortgage Professionals

Moody's Analytics has announced the launch of the Certification of Professional Competence in Mortgage Lending in Hungary, in collaboration with the Budapest Institute of Banking (BIB) and the International Training Center for Bankers (ITCB).

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190609005060/en/

The certification program meets the requirements of the European Parliament and Council Directive on Mortgage Credit. The objective of the mandate is to ensure a minimum standard of competency and ethics among mortgage lenders, specifically applicable to the following roles:
- Bank professionals in the front, middle and back office engaged in residential mortgage lending (for example, product design, underwriting, administration and management, as well as selling)
- Mortgage brokers who propose, offer, and/or sell residential mortgages
- Managers of employees listed above
- Individuals aspiring to work in any position related to the Hungarian mortgage market

Beyond meeting regulatory requirements, the program is designed to elevate the consultative skills of lending professionals and help them become responsible advisers to their customers, in line with the objectives of Hungarian banks and the evolving expectations of the market.

The program delivers a modern learning experience by using advanced technology to personalize the learning and expedite the impact while minimizing the workload for those who already possess the required skills.

Gergely Fábián, Chief Executive Officer of BIB, noted, “We are delighted to work with Moody’s Analytics and to bring their educational framework and professional knowledge in mortgage lending to Hungary. The program aims to instill best practices in lending for mortgage lenders in the Hungarian Banking industry.”

Béla Öcsi, Chief Executive Officer of the ITCB, added, “The innovative Credit Coach framework from Moody’s Analytics brings an enhanced learning experience for all participants. We are pleased to be able to deliver substantial value to the local banking sector through the collaboration with BIB and Moody’s Analytics.”

“We are honored to collaborate with the BIB and ITCB to deliver a program that represents the highest standards in international credit practices, adapted to the unique context of the Hungarian banking industry,” added Ari Lehavi, Executive Director at Moody’s Analytics. “We look forward to supporting similar institutes across the region in their goal of addressing the certification requirements of the European Mortgage Credit Directive, as applicable in their local market.”

Moody’s Analytics recently collaborated with the Hellenic Banking Institute to offer the Certification of Professional Competence in Mortgage Lending program in Greece.

Click here to learn more about Moody’s Analytics Learning Solutions, including Credit Coach.

About Moody’s Analytics

Moody’s Analytics provides financial intelligence and analytical tools to help business leaders make better, faster decisions. Our deep risk expertise, expansive information resources, and innovative application of technology help our clients confidently navigate an evolving marketplace. We are known for our industry-leading and award-winning solutions, made up of research, data, software, and professional services, assembled to deliver a seamless customer experience. We create confidence in thousands of organizations worldwide with our commitment to excellence, open mindset approach, and focus on meeting customer needs. For more information about Moody’s Analytics, visit our website or connect with us on Twitter or LinkedIn .

Moody's Analytics, Inc. is a subsidiary of Moody's Corporation (NYSE: MCO). Moody’s Corporation reported revenue of $4.4 billion in 2018, employs approximately 13,200 people worldwide and maintains a presence in 42 countries.

About the Budapest Institute of Banking

The foundation of the Budapest Institute of Banking (BIB) is rooted in the matching of market needs with the social responsibility objectives of the Magyar Nemzeti Bank (the Central Bank of Hungary) and the Budapest Stock Exchange.

A modern education centre has been created where up-to-date knowledge is transferred in the form of experience-based learning. Forms of edutainment are an integral part of the teaching methodology. Covering the entire operational range of the banking, financial, and insurance sector, the courses grant the opportunity to participants, from experts to top managers, to gain cutting-edge knowledge and to discover professional development opportunities.

The BIB aims to train experts who will be able to address the challenges of the future.

For more information please visit our website: https://www.bib-edu.hu/en .

About International Training Center for Bankers (ITCB)

Founded 30 years ago, ITCB has been providing quality financial education and specialized risk consultancy services for the banking sector in Hungary, Central and Eastern Europe and the Middle East. Building on its long track record and synergies between advisory and training, ITCB’s current offering focuses on tailor-made case study-driven banking seminars, e-learning courses and financial simulations. For more information about ITCB, visit our website .

Contact:

KATERINA SOUMILOVA Moody’s Analytics Communications +1.212.553.1177

Moody's Analytics Media Relations

moodysanalytics.com twitter.com/moodysanalytics linkedin.com/company/moodysanalytics

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release

Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he

Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release

Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release

Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release

The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye